Abstract |
Sendai virosomes can deliver encapsulated contents into the cytoplasm directly in a virus fusion-dependent manner. In this paper, Sendai virosomes-formulated melanoma vaccine was constructed and its anti- tumor effects were investigated. The melanoma vaccine was prepared by encapsulating mixture antigen into the Sendai virosomes. The antigen, mixture proteins were extracted from B(16) melanoma cells. The cytotoxic T lymphocyte (CTL) response level was evaluated by (51)Cr release method, and the change of CD4(+) and CD8(+) expression as well as the concentration of IgG in serum of immunized mice was measured. The results showed that Sendai virosomes-formulated melanoma vaccine can effectively elicit not only systemic immune response but also strong CTL response. Sendai virosomes can be used as an effective vector for use in anti- tumor vaccine therapy.
|
Authors | Qiang Li, Jian-Qing Gao, Li-Yan Qiu, Fu-De Cui, Yi Jin |
Journal | International journal of pharmaceutics
(Int J Pharm)
Vol. 329
Issue 1-2
Pg. 117-21
(Feb 01 2007)
ISSN: 0378-5173 [Print] Netherlands |
PMID | 17046184
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cancer Vaccines
- Virosomes
|
Topics |
- Animals
- Cancer Vaccines
(administration & dosage, immunology, therapeutic use)
- Drug Delivery Systems
- Female
- Melanoma, Experimental
(drug therapy, immunology)
- Mice
- Mice, Inbred C57BL
- Sendai virus
(immunology)
- Virosomes
(administration & dosage, immunology)
|